Kymera Therapeutics, Inc. (KYMR): R&D Expense
$316.57M
Year ended 2025-12-31
$375.57M
Trailing 12 months to 2026-06-30
+24.4%
3-year compound annual growth
+38.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $316.57M | +31.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $240.25M | +27.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $189.08M | +15.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $164.25M | +19.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $137.02M | +120.6% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $62.10M | +67.1% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $37.16M | n/a | 2022-02-24, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $316.57M | +31.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $250.0K | -18.6% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
Compare KYMR, SGMOQ, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗